- Home
- PLBC vs RIGL Comparison
PLBC vs RIGL Comparison
Compare PLBC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- RIGL
- Stock Information
- Founded
- PLBC 1980
- RIGL 1996
- Country
- PLBC United States
- RIGL United States
- Employees
- PLBC N/A
- RIGL N/A
- Industry
- PLBC Finance Companies
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- RIGL Health Care
- Exchange
- PLBC Nasdaq
- RIGL Nasdaq
- Market Cap
- PLBC 288.9M
- RIGL 537.6M
- IPO Year
- PLBC 2005
- RIGL 2000
- Fundamental
- Price
- PLBC $43.00
- RIGL $42.26
- Analyst Decision
- PLBC Buy
- RIGL Buy
- Analyst Count
- PLBC 4
- RIGL 6
- Target Price
- PLBC $56.25
- RIGL $39.83
- AVG Volume (30 Days)
- PLBC 9.3K
- RIGL 652.5K
- Earning Date
- PLBC 10-15-2025
- RIGL 11-04-2025
- Dividend Yield
- PLBC 2.85%
- RIGL N/A
- EPS Growth
- PLBC N/A
- RIGL 2698.26
- EPS
- PLBC 4.23
- RIGL 6.20
- Revenue
- PLBC $89,868,000.00
- RIGL $282,076,000.00
- Revenue This Year
- PLBC $21.11
- RIGL $59.93
- Revenue Next Year
- PLBC $16.11
- RIGL N/A
- P/E Ratio
- PLBC $9.98
- RIGL $6.77
- Revenue Growth
- PLBC 12.51
- RIGL 79.13
- 52 Week Low
- PLBC $38.71
- RIGL $14.63
- 52 Week High
- PLBC $51.33
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- PLBC 52.30
- RIGL 71.17
- Support Level
- PLBC $40.35
- RIGL $34.00
- Resistance Level
- PLBC $43.50
- RIGL $39.56
- Average True Range (ATR)
- PLBC 0.63
- RIGL 2.32
- MACD
- PLBC 0.20
- RIGL 1.15
- Stochastic Oscillator
- PLBC 58.73
- RIGL 97.43
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.